newsfilter
← Latest News
GlobeNewswire·

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through